Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice
<p> <b>A.V. Kuroyedov<sup>1,2</sup>, O.V. Gapon’ko<sup>1,2</sup>, V.V. Gorodnichiy<sup>1</sup>, S.V. Diordiychuk<sup>1</sup>, I.V. Kondrakova<sup>1</sup>, N.M. Sol’nov<sup>1</sup>, N.E. Fomin<su...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Prime-Media
2020-11-01
|
| Series: | РМЖ "Клиническая офтальмология" |
| Online Access: | http://clinopht.com/upload/iblock/e0f/e0f0ad6eb54a8f723be23cf395cb0ca8.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p>
<b>A.V. Kuroyedov<sup>1,2</sup>, O.V. Gapon’ko<sup>1,2</sup>, V.V. Gorodnichiy<sup>1</sup>, S.V. Diordiychuk<sup>1</sup>, I.V. Kondrakova<sup>1</sup>, N.M. Sol’nov<sup>1</sup>, N.E. Fomin<sup>1,2</sup></b>
</p>
<p>
<b><sup>1</sup>P.V. Mandryka Military Clinical Hospital, Moscow, Russian Federation</b>
</p>
<p>
<b><sup>2</sup>Pirogov Russian National Research Medical University, Moscow, Russian Federation</b>
</p>
<p>
<i><b>Aim</b>: to assess the effectiveness and tolerability of anti-VEGF agents, aflibercept (2.0 mg) and ranibizumab (0.5 mg), in the combined treatment for wet age-related macular degeneration (AMD) in routine clinical practice.</i>
</p>
<p>
<i><b>Patients and Methods:</b> 55 patients (65 eyes) with the late stage of wet AMD were divided into two groups. Group 1 included 32 eyes with classic choroidal neovascularization (CNV) and group 2 included 33 eyes with occult CNV. Best-corrected visual acuity (BCVA), intraocular pressure, and retinal nerve fiber layer (RNFL) thickness were measured. These parameters were compared at different time points during the treatment.</i>
</p>
<p>
<i><b>Results</b>: overall AMD duration (January 2019) was 36 (19; 47) months being 30 (12; 44) months in group 1 and 36 (23; 48) months in group 2 (р>0.05). The first intravitreal administration of an anti-VEGF drug was performed 7.5 (3.5; 9.5) months after AMD diagnosis in group 1 and 7 (3; 11) months after AMD diagnosis in group 2. Significant differences in intragroup intervals were revealed between various follow-up periods. More differences were identified for the intervals between intravitreal administrations in group 2. Baseline and final BCVA during the entire follow-up which was 29.5 (19.5; 38) months in group 1 and 28 (25; 44) months in group 2 demonstrated neither intragroup nor intergroup differences (р>0.05).</i>
</p>
<p>
<i><b>Conclusion</b>: our management strategy for wet AMD is somewhat different from conventional guidelines. However, it has no significant impact on visual acuity during the follow-up.</i>
</p>
<p>
<i><b>Keywords</b>: age-related macular degeneration, anti-VEGF drugs, intravitreal administration, IOP level, aflibercept, ranibizumab.</i>
</p>
<p>
<i><b>For citation: </b>Kuroyedov A.V., Gapon’ko O.V., Gorodnichiy V.V. et al. Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice. Russian Journal of Clinical Ophthalmology. 2020;20(4):209–215. DOI: 10.32364/2311-7729-2020-20-4-209-215.</i>
</p>
<i><br>
</i><br> |
|---|---|
| ISSN: | 2311-7729 2619-1571 |